Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.
Bedrijven · 22-6-20011 min lezen
Serono, Inc.; Withdrawal of Approval of a New Drug Application; Breokinase®
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
The Food and Drug Administration (FDA) is withdrawing, without prejudice, approval of a new drug application (NDA) for Breokinase (Urokinase for Injection) held by Serono, Inc., 100 Longwater Circle, Norwell, MA 02061. Serono, Inc., notified the agency in writing that it does not intend to introduce Breokinase into the U.S. market or export Breokinase from the United States, and voluntarily requested that the approval of the application be withdrawn and thereby waived its opportunity for a hearing.
Oorspronkelijke brontaal: Federal Register — Food and Drug AdministrationOrigineel bericht openen →